← Back to Search

LifeExtend-AI for Breast Cancer

N/A
Waitlist Available
Led By Tarah Ballinger, MD
Research Sponsored by Indiana University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Prior SERM and now switching to an AI for the first time is allowed.
Regular access to a smartphone capable of downloading the application
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial will test a mobile health strategy to help early stage breast cancer survivors manage their symptoms, medication, and lifestyle. Results will be used to predict who would most benefit from this type of care.

Eligible Conditions
  • Breast Cancer
  • Ductal Carcinoma

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
Previously, people were allowed to take SERMs (selective estrogen receptor modulators) and switch to using AI (aromatase inhibitors) for the first time.
Select...
The iPhone5, the iPhone SE, or any newer model of the iPhone that runs iOS 11 or later can use AirDrop.
Select...
Android 6 or later versions are currently available
Select...
Concurrent cancer medications are not allowed.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Participants who use the LifeExtend-AI application 5 or more days per week
Secondary outcome measures
Mean medication adherence using the Brief Medication Questionnaire (BMQ)
Mean pain score of self -reported aromatase inhibitor arthralgia using the Basic Pain Inventory (BPI)
Mean quality of life score, measured by the Functional Assessment of Cancer Therapy- Endocrine symptoms (FACT-ES)
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Mobile Health Application InterventionExperimental Treatment1 Intervention
LifeExtend-AI (LX-AI) will be piloted by adding Aromatase Inhibitor (AI)- specific features to LifeExtend, an already existing healthy lifestyle behavior application produced by LifeOmic. This application includes features for tracking activity, diet, sleep, and body weight, as well as creating "to-do" lists and participating in closed social networking for support and encouragement. LifeExtend-AI will add features to track AI adherence and patient-reported joint pain, with alerts sent to both the participant and the healthcare team in response to these parameters. In addition, the app contains educational videos and articles, to which articles addressing management of AI- related toxicities (including exercise) will be added.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LifeExtend-AI
2020
N/A
~70

Find a Location

Who is running the clinical trial?

Indiana UniversityLead Sponsor
976 Previous Clinical Trials
983,315 Total Patients Enrolled
15 Trials studying Breast Cancer
3,508 Patients Enrolled for Breast Cancer
Tarah Ballinger, MDPrincipal InvestigatorIndiana University
6 Previous Clinical Trials
251 Total Patients Enrolled
3 Trials studying Breast Cancer
188 Patients Enrolled for Breast Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who else is applying?

What state do they live in?
Indiana
How old are they?
18 - 65
What site did they apply to?
Indiana University Melvin & Bren Simon Cancer Center
What portion of applicants met pre-screening criteria?
Met criteria
~12 spots leftby Mar 2025